For GA, secondary to AMD

YOUR NAVIGATOR FOR


PATIENT SUPPORT Arrow Icon
Woman smiling and looking at the camera

Welcome to Access Support Navigator, your dedicated destination for navigating access and reimbursement information for SYFOVRE️.

Choose an option below to start navigating.

ApellisAssist® Logo

The ApellisAssist program is designed to help your patients address access barriers to treatment.

LEARN ABOUT THE PROGRAMGO TO THE iASSIST PORTALGo to external site
Paper with checkmark

Billing and Coding

Discover information and resources related to the billing and coding process for SYFOVRE.

GO TO BILLING AND CODING
Hand with checkmark

Payer Coverage

Understand payer coverage for SYFOVRE, including policies for individual plans in your area, as well as information on how to navigate the Prior Authorization (PA) process.

LOOK UP PAYER POLICIES
Calculator

Financial Assistance

Financial assistance is available for eligible patients with different types of insurance, or none at all.

SEE FINANCIAL HELP OPTIONS
Forms

Forms and Resources

Explore our library of downloadable access and reimbursement resources.

EXPLORE RESOURCES

What to expect when accessing SYFOVRE

Support is available for patients throughout the treatment journey.
Here’s what to expect from each step in the process:

1
Paper folded

Enrollment in ApellisAssist

Start by enrolling your patients in the ApellisAssist program. You can enroll online, or download and fax the completed Enrollment Form to 888-405–6966. An Apellis Field Reimbursement Manager (FRM) can share details about the program’s patient support services.

ENROLL NOW
2
Magnifying glass

Benefits Investigation and Access Support

Once a patient is enrolled in ApellisAssist, an Apellis Care Educator (ACE) will contact your practice to help address any potential barriers to access. ACEs are trained to provide assistance and/or information on a range of topics including:

  • Insurance support
  • Financial assistance options for eligible patients
  • Prior authorizations and appeals
NAVIGATE TO APELLISASSIST
3
Calculator

Financial Assistance

Once enrolled, ApellisAssist will assess financial assistance options for eligible patients, based on their insurance types.

NAVIGATE TO FINANCIAL ASSISTANCE
4
Plus inside of a circle

Access and Reimbursement Information

If you need assistance with a denied claim or other access issues for SYFOVRE, you can contact an Apellis Field Reimbursement Manager (FRM).

NAVIGATE TO BILLING AND CODING

Click here to get in touch with an Apellis Field Reimbursement Manager.

Learn more about what to expect with our
step-by-step Access and Reimbursement Guide.

DOWNLOADDownload resource

AMD=age-related macular degeneration; GA=geographic atrophy.

Back to top of page button Back to top of page button

IMPORTANT SAFETY INFORMATION 

INDICATION

CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with hypersensitivity to pegcetacoplan or any of the excipients in SYFOVRE. Systemic hypersensitivity reactions (e.g., anaphylaxis, rash, urticaria) have occurred.

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments

    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

  • Retinal Vasculitis and/or Retinal Vascular Occlusion

    • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.

  • Neovascular AMD

    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.

  • Intraocular Inflammation

    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.

  • Increased Intraocular Pressure

    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Please see full Prescribing Information for more information